C6K0
Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. Its lead asset includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its nam… Read more
C6K0 (C6K0) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.179x
Based on the latest financial reports, C6K0 (C6K0) has a cash flow conversion efficiency ratio of -0.179x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-16.36 Million) by net assets (€91.55 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
C6K0 - Cash Flow Conversion Efficiency Trend (2021–2024)
This chart illustrates how C6K0's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
C6K0 Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of C6K0 ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
FIRST SAVINGS FINL DL-01
F:8N4
|
N/A |
|
Suzhou Longjie Special Fiber Co Ltd
SHG:603332
|
-0.394x |
|
AVY Precision Technology
TWO:5392
|
0.008x |
|
Dogu Aras Enerji Yatirimlari AS
IS:ARASE
|
0.075x |
|
Owens & Minor Inc
NYSE:OMI
|
0.402x |
|
PI Advanced Materials Co. Ltd
KQ:178920
|
0.051x |
|
ELLINGTON RESID.MTG SBI
F:73Z
|
N/A |
|
Concrete Pumping Holdings Class A
NASDAQ:BBCP
|
0.050x |
Annual Cash Flow Conversion Efficiency for C6K0 (2021–2024)
The table below shows the annual cash flow conversion efficiency of C6K0 from 2021 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €133.03 Million | €-49.06 Million | -0.369x | +91.22% |
| 2023-12-31 | €7.30 Million | €-30.68 Million | -4.200x | -271.39% |
| 2022-12-31 | €-10.91 Million | €-26.75 Million | 2.451x | +179.80% |
| 2021-12-31 | €23.08 Million | €-70.89 Million | -3.071x | -- |